Autologous Transplantation in Relapsed or Refractory Hodgkin’s Lymphoma – The Challenges

Abstract

Touch MEdical MEdia 121 Abstract Failure to initiate treatment remains a challenge in Hodgkin’s lymphoma (HL). For years, chemotherapy and stem cell transplantation salvaged less than half of relapses. Nowadays, positron emission tomography can predict the outcome under treatment. Two targeted agents are dramatically improving therapy, alone or in association with chemotherapy or stem cell transplantation. Brentuximab vedotin is an immunoconjugate anti-CD30 and anti-programmed death 1 nivolumab induces blockade of immune checkpoint. How to use them are discussed in the context of relapses/refractory HL.